lefradafiban
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1998 (NCT02264106)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Integrin alpha-IIbINHIBITOR
ITGA2B inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)C[C@@H]1C[C@@H](COc2ccc(-c3ccc(C(=N)NC(=O)OC)cc3)cc2)NC1=O- Mol. weight
- 439.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL2105032 ↗
Also known as
- 5-((((4'-(imino(methoxycarbonyl)amino)methyl)(1,1'-biphenyl)-4-yl)oxy)methyl)-2-oxo-pyrrolidineacetic acid, methyl ester
- lefradafiban
- lefradafiban
- lefradafiban
- lefradafiban
- lefradafiban
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02265289 | Phase 1 | Jan 1, 1999 | Boehringer Ingelheim |
| NCT02264106 | Phase 1 | Apr 1, 1998 | Boehringer Ingelheim |
| NCT02264119 | Phase 1 | Apr 1, 1998 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 1998 |
1 organizations
Page 1 / 1